Goldman Sachs 47th Annual Global Healthcare Conference 2026
Logotype for Medline Inc

Medline (MDLN) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Medline Inc

Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

9 Jun, 2026

Quality and recall management

  • Recent FDA warning letter at the Waukegan facility was anticipated due to self-identified issues; plant was proactively shut down for remediation.

  • Recalls are voluntary, with 15 this year and 29 last year, out of 190,000 products; response focuses on minimizing customer impact and maintaining supply.

  • Redundancy in manufacturing and distribution allows for rapid product replacement and fulfillment during recalls.

  • Significant investments in quality, including $10 million in the Waukegan plant and a global quality team of 2,700+ people.

  • Financial impact of recalls and plant shutdowns is not material, and guidance remains unchanged.

Financial performance and guidance

  • First quarter organic growth reached about 10%, with overall growth near 11% unadjusted and 13% adjusted for days.

  • Acute care channel grew close to 12%, non-acute at 7%, and international at 10%.

  • Full-year organic sales guidance raised to 8.5%-9.5% due to strong demand and share gains.

  • Guidance incorporates potential softness in patient volume in the second half, but higher acuity and utilization offset volume declines.

  • EBITDA guidance for the year is $3.5-$3.6 billion, with stronger performance expected in the second half due to tariff relief and seasonality.

Business drivers and growth strategy

  • Prime vendor contracts are a key driver, with $2.4 billion sold last year, above the $1 billion annual target.

  • Outsized wins attributed to delayed price increases, value positioning, and healthcare consolidation.

  • Medline brand penetration typically doubles in the first year of new contracts, with ongoing incremental gains in subsequent years.

  • Lab and diagnostics, surgical solutions, and frontline care segments are all contributing to growth, with lab and diagnostics expected to recover in the back half.

  • Large addressable market remains, with significant share opportunities in acute care, post-acute, surgery centers, and physician offices.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more